###### Significance of this study

What is already known on this subject?
======================================

-   Inherited predisposition to colorectal, gynaecological, urinary tract, upper gastrointestinal and other cancers may be caused by pathogenic variants of mismatch repair (*path*\_*MMR*) genes and is then commonly referred to as Lynch syndrome (LS).

-   Most patients with LS undergoing surveillance nonetheless develop colorectal and/or other cancers but often survive both their first cancer and their subsequent cancers.

-   Penetrance and expressions of the different *path_MMR* genes in older age are uncertain.

What are the new findings?
==========================

-   Prostate, urinary tract, gastric, duodenal, bile duct and pancreatic cancers occurred frequently in older patients with LS.

-   Prostate and urinary tract cancers predominantly occurred in *path_MSH2* carriers.

-   Upper gastrointestinal tract cancers predominantly occurred in *path_MLH1* carriers.

-   Ovarian cancer occurred predominantly in younger women, which is in contrast to ovarian cancers in *path_BRCA1/2* carriers and in the general population.

-   Survival was very poor for bile duct and pancreatic cancers, intermediate for gastric, duodenal and urinary tract cancers and good for prostate cancer.

-   Except for endometrial and prostate cancer, typical LS cancers were not diagnosed in *path_PMS2* carriers.

How might it impact on clinical practice in the foreseeable future?
===================================================================

-   Knowledge of *path_MMR* gene-specific incidence and survival of cancers affecting different organs will inform genetic counselling and clinical management in the ageing LS population.

-   Risk assessment and surveillance in LS should be based on age, gender and the *path*\_*MMR* gene involved.

-   Subgroups of patients with LS defined by age and *path_MMR* gene have high risks for different cancers, some with serious prognoses in older age.

-   Prevention and cure of these late onset cancers is a growing clinical challenge in LS.

Introduction {#s1}
============

Lynch syndrome (LS) is associated with a high probability of gastrointestinal, gynaecological and other cancers.[@R1] It is caused by germline pathogenic variants in any of four DNA *MMR* genes referred to here as *path*\_*MSH2*, *path_MLH1*, *path_PMS2* or *path*\_*MSH6* and collectively as *path_MMR.* Deletions in the *EPCAM* gene, which lead to inherited methylation of the adjacent *MSH2* promoter, are also referred to as *path*\_*MSH2*. To date, most patients with LS have been identified following investigation because of their family or personal history of multiple and/or early onset cancers.

Carriers of *path_MMR* variants require reliable information about their future cancer risks so that they can be offered appropriately targeted surveillance. However, a paucity of prospectively obtained information has led current clinical guidelines to rely heavily upon retrospective data from patient cohorts whose selection for molecular testing has been subject to bias. The efficacy of effects of interventions to prevent cancers in *path_MMR* carriers is debated.[@R1]

Most patients with LS receiving surveillance for LS-associated tumours develop colorectal, gynaecological or other cancers and now survive both their first and subsequent cancers.[@R1] The consequence is a growing and ageing population of patients with LS. There is limited information on their cancer risks and survivals. One reason for this is that in former generations most patients with LS died from their first cancer, and the risks for survivors are therefore difficult to determine from retrospective family studies.[@R5] A second reason is that measures to prevent or cure early onset cancers in LS are recent developments that have benefited mainly younger patients with LS. A third reason is the possibility that patients with LS affected by cancer at younger ages might have *path_MMR* variants of higher penetrance (as in *path_BRCA1* [@R6]) and/or carry genetic modifiers that increase penetrance[@R7] and/or were exposed to a more carcinogenic environment (as for *path_RB* [@R8]).

Indeed, it was unknown whether LS patients with and without early onset cancer had similar risks for cancer later in life. If the risks differed substantially, these groups could not be pooled when assessing risks in older patients. The first report from the Prospective Lynch Syndrome Database (PLSD) described LS patients without cancer before their inclusion and showed that the different *path_MMR* genes had different penetrance and/or expression.[@R1] Few previous prospective reports had stratified results this way and the question of whether LS patients with early onset cancer have an increased risk for subsequent cancer could be confounded by differences related to which *path_MMR* gene the patients carried. We examined this issue further in a second report from PLSD and found similar future cancer incidence in patients with LS who had a previous cancer compared with those who did not, when stratifying by *path_MMR* gene.[@R2] These findings allowed us to combine the two groups in the present report.

No single centre has sufficient patient numbers to estimate risks in older individuals and international multicentre collaboration is needed to obtain results within a reasonable timeframe. The PLSD provides sufficient numbers for calculation of cumulative incidences of cancer by organ, *path_MMR* variant and gender up to 75 years of age with reasonable precision. For some groups, we also present some figures for cumulative incidences up to 80 years of age.

In our two former reports[@R1], we demonstrated differences in the penetrance and/or expression between pathogenic variants of the four *MMR* genes *MLH1*, *MSH2*, *MSH6* and *PMS2*, and we demonstrated that within each group of path_MMR carriers, the annual incidences of cancers were age dependent. We also demonstrated that for carriers of pathogenic variants of a given *MMR* gene, annual incidence rates of cancers were similar in those who had a previous (early) cancer and those who did not. That is, cancers appeared to be age-dependent stochastic events and any putative differences in penetrance between carriers who had or did nor have an early cancer, including influences of inherited genetic modifiers and environmental factors could be ignored when compiling the current report based on the combined series of both sets of patients. We emphasise that while such factors may be important determinants of penetrance, it is nonetheless legitimate to combine the data from the previous reports and calculate results for the current report without them being subject to major confounders because of these factors.

This report together with the two former reports now provide information relevant to personalised medical care for patients with LS of any age, gender, with or without previous cancer and with any *path_MMR* variant.

Methods {#s2}
=======

Recruitment and follow-up {#s2a}
-------------------------

PLSD database design and inclusion criteria have been described previously.[@R1] This study is an open observational study without a control group. *Path_MMR* carriers aged 25 years or older on the day of their first prospectively planned and completed surveillance colonoscopy were included whether they had previous cancer. We have reported previously time to first cancer[@R1] and time to any subsequent cancer[@R2] up to 70 years in these patients. Any cancers that were diagnosed before or at the same age as the first prospectively planned and completed colonoscopy were scored as previous cancers, and all incident cancers reported here were detected at an older age than the age at inclusion. All patients received follow-up surveillance as reported previously (1-2, see online[Supplementary table S1](#SP1){ref-type="supplementary-material"}) until the last update of information when they were scored as alive or dead. All patients were followed up according to local clinical guidelines. Follow-up times were censored if a patient was lost to follow-up. Intervals between colonoscopies were not considered. Each patient was censored at the age at which the last information was available, which might have been a colonoscopy, any other clinical examination, a report from an examination done by others, or information that the patient had died, whichever came last. In this report, we consider only incidences and survival of cancers in patients with LS undergoing surveillance. As we found that cancers continued to occur, we are planning future studies to investigate the relationships between factors such as colonoscopy interval, adenoma detection and removal and the incidence and stage at diagnoses of colorectal cancer.
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All patients were demonstrated to be carriers of *path_MMR* variants (as determined by reporting centres) by gene testing or were obligate carriers of familial *path_MMR* variants by pedigree structure. All reported *path_MMR* variants were checked against the Leiden Open Variation Database (LOVD) for LS (<http://chromium.lovd.nl/LOVD2/colon_cancer/>) in October 2015. Deletions in the *EPCAM* gene that silence *MSH2* were scored as *path_MSH2*. In sum 1865 (59.7%) of the patients had pathogenic (class 5) variants, 42 (1.3%) patients had probably pathogenic (class 4) variants and the remaining 1212 (38.9%) patients had variants that were not found in LOVD.

The following information was used for analyses: gender, *path_MMR* variant, age at inclusion, age at last update, age at any cancer, cancers scored by the first three positions in the International Classification of Diseases version 9 (ICD9) diagnostic system and age at death. Cancer stage at diagnosis was not included.

Some centres have reported prospective findings independently[@R9] and their previously reported cases are included in the present series.

### Statistical methods {#s2a1}

The statistical methods were described in detail previously.[@R1] In short, annual incidence rates (AIRs) by age were calculated in 5-year cohorts from 25 to 75 years of age. Cumulative incidence, denoted by Q, was computed starting at age 25, assuming zero incidence before age 25, using the formula Q(age) = Q(age−1)+\[1−Q(age−1)\]·AIR(age) where AIR(age) is the annual incidence rate as estimated from the corresponding 5-year interval. The 95% CIs were estimated as appropriate.

When calculating the AIR for a given cancer, only patients without previous cancer in that organ were included, and observation time was censored at first cancer in the organ, while cancers in other organs were ignored. This was considered appropriate based on our reported findings that LS patients with previous cancer have approximately the same incidence of subsequent cancers as those with no previous cancer.[@R1] This way of calculating organ-specific cumulative incidences is in line with the established method for reporting cumulative incidence of breast and ovarian cancer separately in carriers of *path_BRCA1/2*.[@R6]

Lifetime cumulative incidence of cancer was calculated as cumulative incidence from 25 to 75 years of age and compared with the population average from the reporting countries as extracted from <http://globocan.iarc.fr> in December 2015. Specific lifetime cumulative incidences for duodenal, colon and rectal cancers were extracted from <http://www-dep.iarc.fr/NORDCAN/NO/frame.asp> in December 2015 for the year 2013. Relative cumulative lifetime risk was calculated as observed cumulative lifetime incidence divided by population cumulative incidence at 75 years. Crude 5-year and 10-year survival following cancer was assessed by the Kaplan-Meier survivor function for patients aged 65 years or less at diagnoses.

Ethics {#s2b}
------

All reporting centres exported only deidentified data to the joint database used for this report. All genetic tests were performed with appropriate informed consent according to local and national requirements for health care and/or research. No named data was exported from participating centres.

Results {#s3}
=======

A total of 3119 patients including 1723 females, and 1396 males met the inclusion criteria. The total number of observation years was 24 475. The numbers of patients and observation years were 1473 and 13 846 for *path_MLH1* carriers; 1060 and 7492 for p*ath_MSH2* carriers; 462 and 2613 for *path_MSH6* carriers; and 124 and 524 for *path_PMS2* carriers. Mean age at inclusion by gene and gender varied from 41.5 to 53.3; carriers of *path_MSH6* and p*ath_PMS2* were significantly older than carriers of *path_MLH1* and *path_MSH2* ([table 1](#T1){ref-type="table"}). Results for *path_PMS2* carriers are given, although numbers are generally insufficient to draw firm conclusions. In all, 813 cancers were diagnosed during follow-up. They affected 618 patients (20% of all patients with a mean of 1.3 cancers per affected patient) (details are given in online [supplementary table S2](#SP2){ref-type="supplementary-material"}). The observed incidences and cumulative incidences may be considered as risks of developing cancers and are discussed as such. Time from last ccolonoscopyto ccolorectalcancer in patients without prior cancer is given in our first report,[@R1] and time from last colonoscopy to colorectal cancer in patients having had a prior cancer is given in our second report[@R2]

10.1136/gutjnl-2017-314057.supp2

###### 

Patients included, follow-up years and age at inclusion stratified on country, gender and *path_MMR* variants

  Group               Sex    Cases    Follow-up years   Age at inclusion                                            
  ------------------- ------ -------- ----------------- ------------------ ---- ------- ------- ------ ---- ------- -------
   All                3119   24 475   7.8               1                  33   ±0.2    43.8    25     79   ±0.46   
                      F      1723     13 534            7.9                1    33      ±0.26   44.6   25   79      ±0.62
  M                   1396   10 941   7.8               1                  30   ±0.29   42.9    25     79   ±0.67   
  Country of origin                                                                                                 
   Finland            952    9212     9.7               1                  30   ±0.38   43.2    25     79   ±0.88   
   Denmark            515    3084     6.0               1                  17   ±0.31   44.4    25     77   ±1.09   
   UK                 386    2229     5.8               1                  17   ±0.4    45.7    25     79   ±1.29   
   Norway             294    2217     7.5               1                  22   ±0.61   44.7    25     79   ±1.47   
   Spain              202    1167     5.8               1                  14   ±0.51   47.6    25     75   ±1.75   
   Germany            179    1276     7.1               1                  29   ±0.76   43.5    25     72   ±1.61   
   Holland            165    898      5.4               1                  28   ±0.88   45.5    25     78   ±2.00   
   Italy              163    1773     10.9              1                  33   ±1.04   35.9    25     65   ±1.42   
   Sweden             159    1568     9.9               1                  27   ±0.88   44.7    25     77   ±2.07   
   Australia          104    1051     10.1              1                  30   ±1.35   39.2    25     70   ±1.99   
  Gene                                                                                                              
   *MLH1*             F      781      7365              9.4                1    33      ±0.41   42.9   25   79      ±0.93
   M                  692    6481     9.4               1                  30   ±0.44   41.5    25     79   ±0.96   
   *MSH2*             F      599      4233              7.1                1    30      ±0.41   44.6   25   77      ±1.02
   M                  461    3259     7.1               1                  27   ±0.45   42.2    25     73   ±1.05   
   *MSH6*             F      276      1633              5.9                1    21      ±0.49   48.7   25   79      ±1.60
   M                  186    980      5.3               1                  28   ±0.61   46.8    25     79   ±1.85   
   *PMS2*             F      67       303               4.5                1    20      ±1.07   47.7   25   78      ±2.73
   M                  57     221      3.9               1                  22   ±0.97   53.3    26     77   ±3.59   

Cumulative incidences of cancer by organ and age {#s3a}
------------------------------------------------

The cumulative incidences of cancers in individual organs or groups of organs from 25 years of age are shown in [tables 2 and 3](#T2 T3){ref-type="table"}. Cumulative incidence at 75 years for any cancer was 76% (95% CI 68.5% to 83.2%), 80% (95% CI 69.8% to 90.9%) and 61% (95% CI 42.7% to 79.0%) for *path_MLH1*, *path_MSH2* and *path_MSH6* carriers, respectively ([table 2](#T2){ref-type="table"}). A higher lifetime incidence for colorectal cancer was seen in *path_MLH1* and *path_MSH2* carriers compared with *path*\_*MSH6* carriers (46% (95% CI 37.8% to 53.9%), 43% (95% CI 33.2% to 52.8%) and 15% (95% CI 3.3% to 26.6%), respectively). Colorectal cancer was not observed in the small number of *path_PMS2* carriers studied. Most colorectal cancer affected the colon rather than the sigmoid or rectum (t[able 3](#T3){ref-type="table"}). Lifetime incidences for endometrial cancer were 43% (95% CI 33.1% to 52.3%); 57% (95% CI 41.8% to 71.6%) and 46% (95% CI 27.3% to 65.0%) for *path_MLH1*, *path_MSH2* and *path_MSH6* carriers, respectively. The corresponding incidences for ovarian cancer were: 10% (95% CI 4.8% to 15.4%), 17% (95% CI 5.7% to 28.0%) and 13% (95% CI 0.1% to 31.2%), respectively. Most gynaecological cancers occurred before the age of 60 years ([tables 2 and 3](#T2 T3){ref-type="table"}). There was a significantly higher incidence of colon cancer in middle-aged path\_*MLH1* males compared with females, but no significant gender differences were observed for colon cancer in *path_MSH2* and *path_MSH6* carriers ([table 4](#T4){ref-type="table"}).

###### 

Cumulative incidence of cancers in groups of organs from 25 years of age up to the age indicated in the column Age, stratified on carriers of *path_MMR* variants in the different genes and 95% CIs in parentheses. Gynaecological cancer include endometrial and ovarian cancer. Upper gastrointestinal cancer include stomach, duodenum, bile duct, gall bladder or pancreas cancer. Genitorurinary tract cancer include urinary bladder, ureter or kidney

  **ICD9**                 **Organ**                             Age                   Cumulative incidence at age (% (95% CI))                                             
  ------------------------ ------------------------------------- --------------------- ------------------------------------------ --------------------- ------------------- ---
                           Any cancer                            40                    16.8 (12.2 to 21.3)                        14.3 (8.0 to 20.3)    0                   0
  50                       40.2 (34.7 to 45.7)                   37.2 (29.4 to 45.1)   18.1 (8.0 to 28.3)                         0                                         
  60                       58.7 (52.8 to 64.6)                   57.6 (49.3 to 65.9)   39.0 (25.8 to 52.2)                        18.2 (0.0 to 41.0)                        
  70                       71.7 (64.7 to 78.7)                   71.6 (61.9 to 81.2)   53.6 (38.6 to 68.6)                        18.2 (0.0 to 41.0)                        
  75                       75.8 (68.5 to 83.2)                   80.4 (69.8 to 90.9)   60.9 (42.7 to 79.0)                        52.1 (0.1 to 100.0)                       
  **153, 154**             Colorectal cancer                     40                    12.7 (8.6 to 16.9)                         8.9 (4.0 to 13.7)     0                   0
  50                       25.0 (20.0 to 30.0)                   19.4 (13.0 to 25.8)   1.8 (0.0 to 5.4)                           0                                         
  60                       34.6 (28.9 to 40.3)                   27.1 (19.9 to 34.3)   5.6 (0.0 to 11.9)                          0                                         
  70                       40.1 (33.5 to 46.7)                   40.8 (31.6 to 50.1)   15.0% (3.3 to 26.6)                        0                                         
  75                       45.8 (37.8 to 53.9)                   43.0 (33.2 to 52.8)   15.0 (3.3 to 26.6)                         0                                         
  **182, 183**             Gynaecological cancer                 40                    5.7 (2.1 to 9.3)                           5.2 (0.2 to 10.2)     4.2 (0.0 to 12.3)   0
  50                       24.6 (18.2 to 30.9)                   25.3 (16.1 to 34.5)   19.2 (6.2 to 32.1)                         0                                         
  60                       41.4 (33.6 to 49.2)                   49.2 (37.9 to 60.4)   36.1 (19.2 to 53.1)                        26.4 (0.8 to 51.9)                        
  70                       47.6 (38.9 to 56.4)                   62.1 (49.1 to 75.0)   54.0 (34.6 to 73.4)                        26.4 (0.8 to 51.9)                        
  75                       49.8 (40.5 to 59.0)                   65.7 (52.2 to 79.1)   54.0 (34.6 to 73.4)                        26.4 (0.8 to 51.9)                        
  **151, 152, 156, 157**   Upper gastrointestinal tract cancer   40                    1.0 (0.0 to 2.1)                           0                     0                   0
  50                       3.3 (1.4 to 5.1)                      1.5 (0.0 to 3.1)      0                                          0                                         
  60                       7.0 (4.3 to 9.7)                      4.1 (1.3 to 6.9)      2.8 (0.0 to 6.7)                           0                                         
  70                       17.1 (12.1 to 22.0)                   6.7 (2.7 to 10.6)     2.8 (0.0 to 6.7)                           0                                         
  75                       21.4 (15.6 to 27.1)                   10.2 (4.1 to 16.3)    6.6 (0.0 to 14.8)                          0                                         
  **188, 189**             Urinary tract                         40                    0.3 (0.0 to 0.9)                           0                     0                   0
  50                       1.3 (0.2 to 2.5)                      3.4 (0.9 to 5.9)      3.0 (0.0 to 7.0)                           0                                         
  60                       3.0 (1.1 to 4.8)                      9.8 (5.6 to 14.0)     5.7 (0.3 to 11.1)                          0                                         
  70                       7.2 (3.8 to 10.6)                     21.3 (14.2 to 28.3)   7.2 (1.1 to 13.3)                          0                                         
  75                       8.0 (4.3 to 11.7)                     24.9 (16.6 to 33.2)   11.0 (1.7 to 20.3)                         0                                         

###### 

Cumulative incidences of individual cancers in carriers of *path_MMR* variants in the different genes from 25 years of age up to the age of 75 are shown. Incidence of breast, endometrial and ovarian cancers were calculated in females and incidence of prostate cancers calculated in men; all others in both genders combined

  ICD9                              Organ                        Age   Cumulative incidence by age (% (95% CI))                                               
  --------------------------------- ---------------------------- ----- ------------------------------------------ --------------------- --------------------- ---------------------
  Colorectal cancer                                                                                                                                           
  153                               Colon                        40    12.9 (8.8 to 17.1)                         8.6 (3.9 to 13.3)     0                     0
                                                                 50    25.7 (20.7 to 30.7)                        20.2 (13.9 to 26.4)   1.8 (0.0 to 5.2)      0
                                                                 60    36.0 (30.4 to 41.6)                        27.3 (20.3 to 34.3)   5.3 (0.0 to 11.2)     0
                                                                 70    41.6 (35.2 to 48.0)                        40.2 (31.3 to 49.1)   14.2 (3.1 to 25.4)    0
                                                                 75    46.7 (39.2 to 54.3)                        42.4 (32.9 to 51.9)   14.2 (3.1 to 25.4)    0
  154                               Sigmoid and rectum           40    1.6 (0.2 to 3.0)                           0.6 (0.0 to 1.8)      0                     0
                                                                 50    3.2 (1.3 to 5.0)                           4.7 (1.7 to 7.7)      0                     0
                                                                 60    6.3 (3.6 to 9.0)                           9.8 (5.5 to 14.1)     3.0 (0.0 to 7.1)      0
                                                                 70    9.2 (5.6 to 12.9)                          13.5 (8.0 to 19.0)    4.6 (0.0 to 9.7)      0
                                                                 75    11.8 (7.2 to 16.4)                         18.3 (10.9 to 25.6)   4.6 (0.0 to 9.7)      0
  Endometrial and ovarian cancer                                                                                                                              
  182                               Endometrium                  40    3.1 (0.4 to 5.8)                           1.5 (0.0 to 4.4)      0                     0
                                                                 50    18.7 (12.9 to 24.5)                        15.9 (7.9 to 23.8)    15.4 (4.1 to 26.8)    0
                                                                 60    34.8 (27.1 to 42.5)                        40.9 (29.2 to 52.6)   33.2 (16.5 to 49.9)   26.4 (0.8 to 51.9)
                                                                 70    40.3 (31.5 to 49.1)                        52.7 (38.7 to 66.8)   46.2 (27.3 to 65.0)   26.4 (0.8 to 51.9)
                                                                 75    42.7 (33.1 to 52.3)                        56.7 (41.8 to 71.6)   46.2 (27.3 to 65.0)   26.4 (0.8 to 51.9)
  183                               Ovaries                      40    2.6 (0.1 to 5.2)                           3.8 (0.0 to 8.0)      4.2 (0.0 to 12.3)     0
                                                                 50    6.8 (2.9 to 10.7)                          10.7 (4.1 to 17.4)    4.2 (0.0 to 12.3)     0
                                                                 60    8.6 (4.0 to 13.2)                          12.3 (5.1 to 19.5)    4.2 (0.0 to 12.3)     0
                                                                 70    10.1 (4.8 to 15.4)                         16.9 (5.7 to 28.0)    13.1 (0.0 to 31.2)    0
                                                                 75    10.1 (4.8 to 15.4)                         16.9 (5.7 to 28.0)    13.1 (0.0 to 31.2)    0
  Upper gastrointestinal cancer                                                                                                                               
  151                               Stomach                      40    0.3 (0.0 to 0.9)                           0                     0                     0
                                                                 50    0.8 (0.0 to 1.7)                           0.5 (0.0 to 1.4)      0                     0
                                                                 60    2.4 (0.7 to 4.0)                           1.6 (0.0 to 3.4)      1.4 (0.0 to 4.2)      0
                                                                 70    6.3 (3.0 to 9.7)                           4.1 (0.8 to 7.5)      1.4 (0.0 to 4.2)      0
                                                                 75    7.1 (3.5 to 10.8)                          7.7 (1.9 to 13.6)     5.3 (0.0 to 13.1)     0
  152                               Duodenum                     40    0.4 (0.0 to 1.1)                           0                     0                     0
                                                                 50    1.1 (0.0 to 2.3)                           1.0 (0.0 to 2.3)      0                     0
                                                                 60    2.1 (0.5 to 3.7)                           2.0 (0.1 to 4.0)      0                     0
                                                                 70    4.1 (1.4 to 6.8)                           2.0 (0.1 to 4.0)      0                     0
                                                                 75    6.5 (2.7 to 10.2)                          2.0 (0.1 to 4.0)      0                     0
  156                               Bile duct and gall bladder   40    0                                          0                     0                     0
                                                                 50    0.3 (0.0 to 0.8)                           0                     0                     0
                                                                 60    1.3 (0.0 to 2.5)                           0                     0                     0
                                                                 70    3.7 (1.3 to 6.2)                           0                     0                     0
                                                                 75    3.7 (1.3 to 6.2)                           1.7 (0.0 to 5.1)      0                     0
  157                               Pancreas                     40    0.3 (0.0 to 0.9)                           0                     0                     0
                                                                 50    1.1 (0.0 to 2.1)                           0                     0                     0
                                                                 60    1.7 (0.3 to 3.1)                           0.5 (0.0 to 1.5)      1.4 (0.0 to 4.2)      0
                                                                 70    3.9 (1.4 to 6.4)                           0.5 (0.0 to 1.5)      1.4 (0.0 to 4.2)      0
                                                                 75    6.2 (2.6 to 9.8)                           0.5 (0.0 to 1.5)      1.4 (0.0 to 4.2)      0
  Urinary tract cancer                                                                                                                                        
  188                               Urinary bladder              40    0                                          0                     0                     0
                                                                 50    0.5 (0.0 to 1.2)                           1.0 (0.0 to 2.3)      2.9 (0.0 to 7.0)      0
                                                                 60    1.9 (0.4 to 3.4)                           3.6 (1.0 to 6.3)      4.3 (0.0 to 9.1)      0
                                                                 70    4.1 (1.5 to 6.7)                           6.2 (2.3 to 10.2)     4.3 (0.0 to 9.1)      0
                                                                 75    4.1 (1.5 to 6.7)                           8.1 (2.8 to 13.3)     8.2 (0.0 to 16.9)     0
  189                               Ureter and kidney            40    0.3 (0.0 to 0.9)                           0                     0                     0
                                                                 50    0.8 (0.0 to 1.8)                           2.4 (0.3 to 4.5)      0                     0
                                                                 60    1.1 (0.0 to 2.2)                           6.9 (3.3 to 10.5)     1.4 (0.0 to 4.2)      0
                                                                 70    3.8 (1.2 to 6.4)                           16.0 (9.6 to 22.4)    3.0 (0.0 to 7.0)      0
                                                                 75    4.6 (1.6 to 7.6)                           17.8 (10.6 to 25.0)   3.0 (0.0 to 7.0)      0
  Other LS or possible LS cancers                                                                                                                             
  174                               Breast                       40    0                                          2.6 (0.0 to 6.2)      0                     0
                                                                 50    2.9 (0.6 to 5.2)                           5.2 (0.7 to 9.8)      0                     0
                                                                 60    8.3 (4.2 to 12.4)                          6.1 (1.3 to 11.0)     4.7 (0.0 to 11.0)     8.6 (0.0 to 24.8)
                                                                 70    12.0 (6.7 to 17.3)                         11.5 (4.6 to 18.4)    13.3 (2.2 to 24.4)    8.6 (0.0 to 24.8)
                                                                 75    12.0 (6.7 to 17.3)                         11.5 (4.6 to 18.4)    13.3 (2.2 to 24.4)    55.9 (0.0 to 100.0)
  185                               Prostate                     40    0                                          0                     0                     0
                                                                 50    0.6 (0.0 to 1.6)                           0                     0                     37.9 (0.0 to 95.9)
                                                                 60    5.3 (1.4 to 9.1)                           4.2 (0.0 to 8.8)      0                     37.9 (0.0 to 95.9)
                                                                 70    13.3 (6.1 to 20.4)                         13.2 (3.7 to 6.1)     4.4 (0.0 to 12.9)     37.9 (0.0 to 95.9)
                                                                 75    16.9 (8.5 to 25.3)                         31.6 (11.7 to 51.5)   18.3 (0.0 to 44.4)    37.9 (0.0 to 95.9)
  191                               Brain                        40    0.3 (0.0 to 0.9)                           0                     0                     0
                                                                 50    0.3 (0.0 to 0.9)                           0                     0                     0
                                                                 60    0.3 (0.0 to 0.9)                           1.1 (0.0 to 2.6)      1.4 (0.0 to 4.2)      0
                                                                 70    1.0 (0.0 to 2.4)                           1.9 (0.0 to 4.0)      1.4 (0.0 to 4.2)      0
                                                                 75    1.0 (0.0 to 2.4)                           5.3 (0.2 to 10.3)     1.4 (0.0 to 4.2)      0

LS, Lynch syndrome

###### 

Cumulative incidence colon and sigmoidal-rectal cancer stratified by age, *path_MMR* variant and gender. There was no observed colon or sigmoid-rectal cancer in *path_PMS2* carriers in any age group (see [table 3](#T3){ref-type="table"})

                                     Age                   Cumulative incidence by age (% (95% CI))                                                                         
  ---------------------------------- --------------------- ------------------------------------------ --------------------- --------------------- --------------------- --- ---
  Colon cancer (ICD9=153)            40                    10.4 (5.2 to 15.6)                         15.4 (9.0 to 21.9)    10.1 (2.9 to 17.3)    7.4 (1.2 to 13.6)     0   0
  50                                 18.8 (12.6to 25.0)    33.3 (25.5 to 41.1)                        23.8 (14.8 to 32.8)   15.8 (7.2 to 24.3)                          0   
  60                                 28.1 (20.9 to 35.2)   45.2 (36.6 to 53.8)\*                      31.4 (21.9 to 41.0)   21.5 (11.3 to 31.6)                             
  70                                 37.3 (28.5 to 46.1)   45.2 (36.6 to 53.8)                        44.7 (33.7 to 55.7)   32.4 (17.7 to 47.2)                             
  75                                 42.1 (31.8 to 52.5)   50.8 (40.1 to 61.5)                        44.7 (33.7 to 55.7)   42.6 (20.4 to 64.9)                             
  Sigmoid- rectal cancer(ICD9=154)   40                    1.4 (0.0 to 3.3)                           1.9 (0.0 to 4.1)      0                     1.3 (0.0 to 3.8)      0   0
  50                                 2.9 (0.3 to 5.4)      3.6 (0.8 to 6.4)                           1.0 (0.0 to 3.0)      8.9 (3.0 to 14.7)     0                     0   
  60                                 6.1 (2.4 to 9.8)      6.5 (2.6 to 10.5)                          4.0 (0.2 to 7.8)      17.9 (9.2 to 26.5)    4.6 (0.0 to 10.7)     0   
  70                                 10.2 (4.9 to 15.6)    7.6 (3.2 to 12.1)                          8.2 (2.2 to 14.3)     20.7 (10.7 to 30.7)   7.0to (0.0 to 14.6)   0   
  75                                 11.7 (5.7 to 17.7)    11.7 (4.7 to 18.7)                         12.9 (4.4 to 21.3)    26.0 (12.3 to 39.7)   7.0 (0.0 to 14.6)     0   

\*Increased (p\<0.05) compared with same-aged females.

\*\*Lower (p\<0.05) than in path_MLH1 or path_MSH2 carrier with same gender and age.

Upper gastrointestinal cancers including those affecting the stomach, duodenum, bile duct, gall bladder or pancreas were diagnosed predominantly in old age. The cumulative lifetime incidence of upper gastrointestinal tumours was particularly high for *path*\_*MLH1* carriers (21% (95% CI 15.6% to 27.1%) compared with *path_MHS2* carriers (10% (95% CI 4.1% to 16.3%)) and *path_MSH6* carriers (7% (95% CI 0% to 14.8%)) ([table 2](#T2){ref-type="table"}). Among upper gastrointestinal cancers, the cumulative risk for stomach cancer was greatest: 7% (95% CI 3.5% to 10.8%) and 8% (95% CI 1.9% to 13.6%) for *path_MLH1* and *path_MSH2* carriers, respectively. Urinary tract cancers also occurred predominantly in older age. Their incidence was elevated particularly in *path_MSH2* carriers: 25% (95% CI 16.6% to 33.2%) compared with *path_MLH1* carriers (8% (95% CI 4.3% to 11.7%)) and *path_MSH6* carriers (11% (95% CI 1.7% to 20.3%)). Ureteric cancer was most prevalent. Cumulative incidences up to 75 years of age by *path_MMR* category for any cancer, upper gastrointestinal cancer and urinary tract cancer are shown in [figure 1](#F1){ref-type="fig"}.

![Cumulative incidences of colorectal cancer, upper gastrointestinal cancer (including stomach, duodenum, bile duct, gall bladder and pancreas) and urinary tract cancer (not including prostate).](gutjnl-2017-314057f01){#F1}

The cumulative incidences at 75 years of age for prostate cancer were 17% (95% CI 8.5% to 25.3%), 32% (95% CI 11.7% to 51.5%) and 18% (95% CI 0% to 44.4%) for *path*\_*MLH1*, *path*\_*MSH2* and *path*\_*MSH6* carriers, respectively. For detailed description of all observation years and incident cancer cases in each 5-year age group, see online [supplementary table S3](#SP3){ref-type="supplementary-material"}.

10.1136/gutjnl-2017-314057.supp3

Relative cumulative incidences {#s3b}
------------------------------

Cumulative incidences at 75 years of age were compared with population incidences to arrive at cumulative relative risk (RR) (see [table 5](#T5){ref-type="table"}). *Path_MLH1*, *path*\_*MSH2* and *path*\_*MSH6* carriers showed an RR of any cancer of 3.1 (95% CI 2.8 to 3.4), 3.3 (95% CI 2.9 to 3.7) and 2.5 (95% CI 1.7 to 3.2), respectively. By genotype, path\_*MLH1* carriers had the highest RR for duodenal (RR 64.7), colon (RR 22.3), bile duct/gall bladder (RR 18.7) and pancreatic cancers (RR 7.8); path*\_MSH2* carriers had the highest RR for endometrial (RR 35.5), ovarian (RR 16.9), urinary tract (RR 10.8) and prostate cancers (RR 3.2). Path*\_MSH6* carriers had similar RR for endometrial and ovarian cancer as path*\_MLH1* and *path_MSH2* carriers (RR 28.8 and 13.0, respectively) but less frequent cancer in other organs. The few *path_PMS2* carriers included had endometrial prostate and breast cancers, but none of the other cancers typically seen in LS were diagnosed ([table 5](#T5){ref-type="table"}).

###### 

Relative cumulative incidence (RR) cancer at 75 years in carriers of *path_MMR* genes stratified by gene. 95% CIs are shown in parentheses. Significantly increased (p\<0.05) RRs are highlighted in bold. Maximum RR by gene underlined

  ICD9                                  Organ                        Population incidence (%)   Relative cumulative incidence (95% CI)                                                       
  ------------------------------------- ---------------------------- -------------------------- ---------------------------------------- ------------------------- ------------------------- --------------------
  Any cancer                            24.4                         3.1 (2.8 to 3.4)           3.3 (2.9 to 3.7)                         2.5 (1.7 to 3.2)          2.1 (0 to 4.1)            
  In separate organs order by RR                                                                                                                                                             
  152                                   Duodenum                     0.1                        **64.7 (27.4 to 102.1)**                 20.1 (0.6 to 39.6)        0                         0
  182                                   Endometrium                  1.6                        **26.7 (20.7 to 32.7)**                  **35.5 (26.1 to 44.8)**   **28.9 (17.1 to 40.6)**   16.5 (0.5 to 32.4)
  153                                   Colon                        2.1                        **22.3 (18.7 to 25.9)**                  **20.2 (15.6 to 24.7)**   **6.8 (1.5 to 12.1)**     0
  156                                   Bile duct and gall bladder   0.2                        **18.7 (6.3 to 31.1)**                   8.6 (0 to 25.4)           0                         0
  183                                   Ovary                        1.0                        **10.1 (4.8 to 15.4)**                   **16.9 (5.7 to 28.0)**    13.1 (0 to 31.2)          0
  189                                   Ureter and kidney            1.3                        **3.5 (1.2 to 5.9)**                     **13.7 (8.2 to 19.2)**    2.3 (0 to 5.4)            0
  154                                   Sigmoid and rectum           1.4                        **8.4 (5.2 to 11.7)**                    **13.0 (7.8 to 18.3)**    3.3 (0 to 6.9)            0
  191                                   Brain                        0.5                        1.9 (0 to 4.8)                           10.5 (0.4 to 20.6)        2.9 (0 to 8.4)            0
  151                                   Stomach                      0.8                        **8.9 (4.4 to 13.4)**                    **9.7 (2.3 to 17.0)**     6.6 (0 to 16.4)           0
  188                                   Urine bladder                1.0                        **4.1 (1.5 to 6.7)**                     **8.1 (2.8 to 13.3)**     8.2 (0 to 16.9)           0
  157                                   Pancreas                     0.8                        **7.8 (3.3 to 12.3)**                    0.6 (0 to 1.9)            1.8 (0 to 5.2)            0
  185                                   Prostate                     10                         1.7 (0.9 to 2.7)                         **3.2 (1.2 to 5.1)**      1.8 (0 to 4.4)            3.8 (0 to 9.6)
  174                                   Breast                       9.4                        1.3 (0.7 to 1.8)                         1.2 (0.5 to 2.0)          1.4 (0.2 to 2.6)          6.0 (0 to 10.6)
  In anatomical regions ordered by RR                                                                                                                                                        
  Gynaecological                        2.6                          **19.1 (15.6 to 22.7)**    **25.3 (20.1 to 30.4)**                  **20.8 (13.3 to 28.2**)   10.1 (0.3 to 20)          
  Colorectal                            3.8                          **12.1 (10 to 14.2)**      **11.3 (8.7 to 13.9)**                   3.9 (0.9 to 7.0)          0                         
  Upper gastrointestinal cancer         1.9                          **11.2 (8.2 to 14.3)**     **5.4 (2.1 to 8.6)**                     3.5 (0 to 7.8)            0                         
  Urinary tract cancer                  2.3                          **3.5 (1.9 to 5.1)**       **10.8 (7.2 to 14.4)**                   4.8 (0.7 to 8.8)          0                         

Survival following cancer {#s3c}
-------------------------

Five-year and 10-year crude survival by affected organ for all cases diagnosed with cancer before 65 years of age are shown in [table 6](#T6){ref-type="table"}. Five-year survival was 96% for colon cancer and 75% for recto-sigmoid cancer. Corresponding 10-year survival was 88% and 70%, respectively. Five-year survival for endometrial cancer was 93% and for ovarian cancer 83%, and corresponding 10-year survival was 93% and 74%, respectively. Among other extracolonic cancers, 5-year survival was also very good for prostate (100%), urine bladder (93%) and ureter and kidney (85%) cancers and remained good at 10 years. Five-year survival for stomach and duodenal cancer was lower at 61% and 67%, respectively, while 5-year survival was poor following bile duct or gallbladder cancer (29%) or pancreatic cancer (0%).

###### 

Five-year and 10-year overall survival calculated by the Kaplan-Meier algorithm stratified on diagnoses for patients prospectively diagnosed \<65 years of age

  ICD9 diagnosis                        Organ                        n     5-year survival   10-year survival        
  ------------------------------------- ---------------------------- ----- ----------------- ------------------ ---- ------------
  Colorectal cancer                                                                                                  
  153                                   Colon                        159   96                91% to 98%         88   77% to 94%
  154                                   Sigmoid rectum               47    75                56% to 87%         70   49% to 84%
  Gynaecological cancer                                                                                              
  182                                   Endometrium                  104   93                85% to 97%         93   85% to 97%
  183                                   Ovary                        25    83                55% to 94%         74   44% to 90%
  Upper gastrointestinal tract cancer                                                                                
  151                                   Stomach                      17    61                33% to 81%         61   33% to 81%
  152                                   Duodenum                     11    67                28% to 88%         67   28% to 88%
  157                                   Pancreas                     10    0                                         
  156                                   Bile duct and gall bladder   8     29                04% to 61%         14   1% to 47%
  Urinary tract cancer                                                                                               
  189                                   Ureter kidney                28    85                64% to 94%         71   34% to 89%
  188                                   Urine bladder                20    93                59% to 99%         81   42% to 95%
  Other                                                                                                              
  185                                   Prostate                     17    100                                  80   20% to 97%
  174                                   Breast                       31    95                70% to 99%         89   61% to 97%
  191                                   Brain                        9     22                3% to 51%          22   3% to 59%

Given the high mortality of some late-onset cancers and the probability that individuals affected by early-onset cancers with good prognoses might have developed and died from such cancers later, we recalculated survival after censoring patients as lost to follow-up when they developed a cancer with \<70% 5-years survival. This did not result in any significant differences. The results of these calculations are illustrated in [figure 2](#F2){ref-type="fig"}.

![Kaplan-Meier estimates of 10-year crude survival following colon cancer, sigmoid-rectal cancer, endometrial cancer or ovarian cancer that was diagnosed before 65 years of age after censoring for upper gastrointestinal or brain tumours. Solid line indicates point values; dotted lines indicate 95% CIs.](gutjnl-2017-314057f02){#F2}

Combining risk for cancer and survival following cancer {#s3d}
-------------------------------------------------------

Data on the risk of cancer affecting an organ and the chance of survival after that cancer occurs may be combined to calculate the risk of dying from a cancer in that organ. This combined risk may be calculated for a patient based on age, gender and *path_MMR* variant. As an example, the cumulative risk for colon cancer in a *path*\_*MSH6* carrier at 60 years is 5%, 10-year survival is 88% and the risk of developing and dying of colorectal cancer before 70 years of age (subject to follow-up according to guidelines) is (5% · 12% =) 0.6%. Other examples may be: the combined risk for a *path_MSH6* carrier of developing and dying from an ovarian cancer before 70 years would be (4% · 26% =) 1%. The combined risk for a *path*\_*MLH1* carrier of developing and dying from bile duct cancer before 80 years would be (4% · 86% =) 3%. It follows from the CIs in [tables 3 and 6](#T3 T6){ref-type="table"} that such calculated combined risks for contracting and dying from specific cancers have wide confidence intervals.

Path\_*MSH2* carriers had a substantial risk of urinary tract and prostate cancers in older ages and most but not all survived these cancers. In this report, the risk of cancer is presented for some ages only. Using our interactive website [www.lscarisk.org](www.lscarisk.org), the risks of cancers may be calculated for patients with LS of any age.

Discussion {#s4}
==========

This study included both LS patients without a previous cancer and patients with LS who had survived early cancer(s), thereby providing numbers that were sufficient to calculate cancer risks stratified by *path_MMR* variant for each organ involved up to 75 years of age. The majority of patients included in the study were *path_MLH1* or *path_MSH2* carriers, and the majority of older patients in these groups had survived previous cancer(s).[@R1] The tables describing cumulative cancer incidences are the results of the study and are discussed below. An interactive website ([www.lscarisk.org](www.lscarisk.org)) based on online [supplementary table S3](#SP3){ref-type="supplementary-material"} allows cancer risks to be calculated for any patients with LS simply by providing the patient's age and gender and represents the applied outcome of the study.

Older *path_MSH2* carriers had a particularly high incidence of urinary tract and prostate cancers, while older *path_MLH1* carriers had the highest incidence of upper gastrointestinal cancers. Survival was very poor for bile duct and pancreatic cancer, intermediate for gastric and urinary tract cancers and good for prostate cancer. These findings demonstrate that genetic subgroups in LS are at risk for different cancers in old age and that these cancers have very different prognoses. Compared with *path_MLH1* and *path_MSH2* carriers, we show that *path_MSH6* carriers are at lower risk for early onset cancer and, except for an intermediate risk for urinary tract or prostate cancer, at lower risk for late onset cancers too.

The current study refines estimates of cancer risk for all patients with LS but in particular provides data that will better inform counselling and clinical management of older patients with LS. Previous reports[@R9] did not include sufficient numbers of patients to stratify cancer risk in older age by *path_MMR* variant, as has been possible here.

Despite its international multicentre design, this study still identified too few *path_PMS2* carriers to draw firm conclusions about their cancer risks. Apart from endometrial and prostate cancer, however, none of the cancers considered to be part of LS were diagnosed in *path_PMS2* carriers.

We calculated the incidence of ovarian or endometrial cancer in female LS patients with censoring at prophylactic oophorectomy or hysterectomy that was undertaken in some patients. In contrast to *path_BRCA1/2* carriers[@R12] and the general population, most ovarian cancers in LS were diagnosed before the menopause, and their prognosis was good. This finding brings into question the practice of recommending prophylactic oophorectomy at the menopause in females with LS.[@R4]

Risks for breast cancer in patients with LS were not increased significantly, and therefore we could not confirm previous reports that have suggested that breast cancer is part of the LS cancer spectrum[@R17]

The structure of the database (PLSD) established for our studies enables us to add any information of interest later for all patients. The results obtained so far raise further questions that we should now investigate, such as the relationships between colonoscopy interval, stage at prospectively detected CRC and its treatment and survival. We have a lot more to do, and we invite further centres to join PLSD so that we can answer these clinically important questions as quickly and as definitively as possible.

The novelty of this report is that we provide for the first time the empirical prospectively observed outcome of healthcare into old ages for patients with LS including stratification by *path_MMR* variant. Before management guidelines are revised to take account of this stratification, validation of the findings of this study should be achieved in at least one other similar but independent study. We are in collaboration with the European Hereditary Tumour Group ([www.mallorca-group.org](www.mallorca-group.org)) and InSiGHT ([www.insight-group.org](www.insight-group.org)) with the aim of establishing an independent series to validate the findings presented here. If our findings are confirmed, we may have a larger combined cohort to narrow the CIs of the observed point estimates before discussing conclusions with respect to clinical guidelines. To this end, we invite other centres with compatible cohorts of patients with LS to contribute. In particular, there is a need for much more data on *path_PMS2* and *path_MSH*6 patients.

This is the first comprehensive study of cancer risk and prognosis in older LS patients stratified by *path_MMR* variant. We have updated our website [www.lscarisk.org](www.lscarisk.org) to include the results presented here. Using the website, the age, gender and *path_MMR* variant in any given patient may now be entered to calculate the remaining lifetime risk for cancer in individual organs. This is likely to be of interest both to patients with LS and their healthcare providers

For further information on the collaborating activities, please visit <http://insight-group.org/> and <http://mallorca-group.org/>.
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